CAR-engineered microglia harness phagocytosis to target brain tumor in organoid models.

Authors

Mu Seog Choe, Woo Sub Yang, Bilal Cakir, Ferdi Ridvan Kiral, Jonghun Kim, Cynthia Lo, Eena Cheng, Benjamin Ongnok, Viswanathan Muthusamy, Nipon Chattipakorn, Siriporn C Chattipakorn, In-Hyun Park

Published in

Cell reports. Volume 45. Issue 10. Pages 118091. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

Glioblastoma (GBM) is among the most aggressive and lethal brain tumors, and standard treatment offers only modest survival benefits. Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic cancers, but its efficacy in GBM remains limited. Here we develop a CAR-engineered microglia (CAR-MG) platform and an organoid-based framework to test whether programmable microglial phagocytosis can be directed against GBM. We isolate microglia (MG) from human cortical organoids and engineer them to express a CAR targeting EGFRvIII, a recurrent tumor-specific EGFR deletion variant in GBM. In a 2D co-culture, CAR-MG selectively eliminates GBM cells through phagocytosis. In a 3D GBM-cortical organoid model, CAR-MG infiltrates tumor sites and depletes GBM cells over extended culture. Single-cell RNA sequencing (scRNA-seq) shows elevated phagocytic pathways in CAR-MG and detects internalized tumor-derived transcripts, which resolve phagocytosis-resistance programs. These results support CAR-MG as a myeloid CAR modality for human brain organoid models.

PMID:
42842373
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.